Population pharmacokinetics of dapsone administered biweekly to human immunodeficiency virus-infected patients

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 12, 1996, Pages 2743-2748

  Gatti, Giorgio ^a,d   Merighi, Mara ^b   Hossein, Javad ^a   Travaini, Silvia ^a   Casazza, Rosetta ^a   Karlsson, Mats ^c   Cruciani, Mario ^b   Bassetti, Dante ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UPPSALA UNIVERSITY   (Sweden)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DAPSONE; DIDANOSINE; RIFAMPICIN;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; BIOAVAILABILITY; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PNEUMOCYSTIS PNEUMONIA; POPULATION RESEARCH; PRIORITY JOURNAL; RECIPIENT; TREATMENT FAILURE;

EID: 0029807559     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.12.2743     Document Type: Article

References (33)

1. Antinori, A., R. Murri, R. Tamburrini, A. De Luca, and L. Ortona. 1992. Failure of low-dose dapsone-pyrimethamine in primary prophylaxis of Pneumocystis carinii pneumonia. Lancet 340:788.
2. Armstrong, D., and E. Bernard. 1990. Aerosolized pentamidine for the prevention and treatment of pneumocystosis. AIDS Updates 3:1-7.
3. 2a. Backman, J. T., K. T. Okkola, and P. J. Neuvonen. 1996. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin. Pharmacol. Ther. 59:7-13.
4. Balakrishnan, S., and P. S. Seshadri. 1970. Drug interaction, the influence of rifampin and clofazimine on the urinary excretion of DDS. Lepr. India 53:17-22.
5. Blum, R. N., L. A. Miller, L. C. Gaggini, and D. L. Cohn. 1992. Comparative trial of dapsone versus trimethoprim/sulfamethoxazole for primary prophylaxis of Pneumocystis carinii pneumonia. J. Acquired Immune Defic. Syndr. 5:141-347.
6. Carr, A., A. S. Gross, J. M. Hoskins, R. Penny, and D. A. Cooper. 1994. Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxasole in HIV-infected patients. AIDS 8:333-337.
7. Clotet, B., G. Sirera, J. Romeu, J. M. Gimeno, A. Jou, M. J. Condom, J. Tor, and M. Foz. 1991. Twice-weekly dapsone-pyrimethamine for preventing PCP and cerebral toxoplasmosis. AIDS 5:601-602.
8. Coker, R. J., R. Nieman, M. McBride, D. M. Mitchell, J. R. Harris, and J. N. Weber. 1992. Co-trimoxasole versus dapsone-pyrimethamine for prevention of Pneumocystis carinii pneumonia. Lancet 340: 1099.
9. Cushion, M. T., D. Stanforth, M. J. Linke, and P. D. Walzer. 1985. Method of testing the susceptibility of Pneumocystis carinii to antimicrobial agents in vitro. Antimicrob. Agents Chemother. 28:796-801.
10. Edstein, M. D., K. H. Rieckmann, and J. R. Veenendaal. 1990. Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine in man. Br. J. Clin. Pharmacol. 30:259-265.
11. Evans, D. A. P. 1989. N-Acetyltransferase. Pharmacol. Ther. 42:157-234.
12. Falloon, J., J. Lavelle, D. Ogata-Arakaki, A. Byrne, A. Graziani, A. Morgan, M. A. Amantea, K. Ownby, M. Polis, R. T. Davey, Jr., J. A. Kovacs, H. C. Lane, H. Masur, and R. R. MacGregor. 1994. Pharmacokinetics and safety of weekly dapsone and dapsone plus pyrimethtamine for prevention of Pneumocystis pneumonia. Antimicrob. Agents Chemother. 38:1580-1587.
13. Gail May, D., P. A. Arns, W. O. Richards, J. Porter, D. Ryder, C. M. Fleming, G. R. Wilkinson, and R. A. Branch. 1992. The disposition of dapsone in cirrhosis. Clin. Pharmacol. Ther. 51:689-700.
14. Gail May, D., J. A. Porter, J. U. Uetrecht, G. R. Wilkinson, and R. A. Branch. 1990. The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects. Clin. Pharmacol. Ther. 48:619-627.
15. Gatti, G., A. Loy, R. Casazza, F. Miletich, M. Cruciani, and D. Bassetti. 1995. Pharmacokinetics of dapsone in acquired immunodeficiency syndrome-infected children. Antimicrob. Agents Chemother. 39:1101-1106.
16. Gelber, R., J. H. Peters, G. R. Gordon, A. J. Glazko, and L. Levy. 1971. The polymorphic acetylation of dapsone in man. Clin. Pharmacol. Ther. 12:225-238.
17. Girard, P.-M., R. Landman, C. Gaudebot, R. Olivares, A. G. Saimot, P. Jelazko, C. Gaudebot, A. Certain, F. Boué, E. Bouvet, T. Lecompte, J.-P. Coulaud, and the PRIO Study Group. 1993. Dapsone-pyrimcthamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. N. Engl. J. Med. 328:1514-1520.
18. Hughes, W. T., W. Kennedy, M. Dugdale, M. A. Land, D. S. Stein, J. J. Weems, Jr., S. Palte, D. Lancaster, S. Gidan-Kovnar, and R. E. Morrison. 1990. Prevention of Pneumocystis carinii pneumonitis in AIDS patients with weekly dapsone. Lancet 336:1066.
19. Kemper, C. A., R. M. Tucker, O. S. Lang, J. M. Kessinger, S. I. Greene, S. C. Deresinski, and D. A. Stevens. 1990. Low-dose dapsone prophylaxis of Pneumocystis carinii pneumonia in AIDS and AIDS-related complex. AIDS 4:1145-1148.
20. Lee, B. L., I. Medina, N. L. Benowitz, P. Jacob III, C. B. Wofsy, and J. Mills. 1989. Dapsone, trimethoprim, and sulfamethoxasole plasma levels during treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome. Ann. Intern. Med. 110:606-611.
21. Lee, B. L., D. Wong, N. L. Benowitz, and P. M. Sullam. 1993 Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin. Pharmacol. Ther. 53:529-535.
22. Mallolas, J., L. Zamora, J. M. Gatell, J. M. Miró, E. Vernet, M. E. Valls, E. Soriano, and J. G. SanMiguel. 1993. Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxasole, aerosolized pentamidine and dapsone plus pyrimethamine. AIDS 7:59-64.
23. Martin, M. A., P. H. Cox, K. Beck, C. M. Styer, and G. N. Beall. 1992. A comparison of the effectiveness of three regimens in the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients. Arch. Intern. Mcd. 152:523-528.
24. NONMEM Project Group. 1992. NONMEM users' guides. In S. L. Beal and L. B. Sheiner (ed.). University of California at San Francisco, San Francisco.
25. Occhipinti, D. J., A. Choi, K. Deyo, L. H. Danziger, and J. H. Fisher. 1995. Influence of rifampin and clarithromycin on dapsone disposition and methemoglobin concentrations, ahstr. OI-B-2. In Abstracts of papers of the 96th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics. American Society for Clinical Pharmacology and Therapeutics, Norristown, Pa.
26. Opravil, M., B. Joos, and R. Luthy. 1994. Levels of dapsone and pyrimethamine in serum during once-weekly dosing for prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. Antimicrob. Agents Chemother. 38:1197-1199.
27. Philip, P. A., M. S. Roberts, and H. J. Rogers. 1984. A rapid method for determination of acetylation phenotype using dapsone. Br. J. Clin. Pharmacol. 17:465-469.
28. Podzamczer, D., M. Santin, J. Jimenez, A. Casanova, F. Bolao, and G. R. F. Gudiol. 1993. Thrice-weekly cotrimoxazole is better than weekly dapsone-pyrimethamine for the primary prevention of Pneumocystis carinii pneumonia in HIV-infected patients. AIDS 7:501-506.
29. Relling, M. V., and W. E. Evans. 1992. Genetic polymorphisms of drug metabolism, p. 7.1-7.32. In V. Evans, J. J. Shentag, and W. J. Jusko (ed.), Applied pharmacokinetics, 3rd ed. Applied Therapeutics, Inc., Vancouver, Wash.
30. Slavin, M. A., J. F. Hoy, K. Stewart, M. B. Pettinger, R. Lucas, and S. J. Kent. 1992. Oral dapsone versus nebulized pentamidine for Pneumocystis carinii pneumonia prophylaxis: an open prospective trial to assess efficacy and haematological toxicity. AIDS 6:1169-1174.
31. Swick, L., J. Sahai, and K. Gallicano. 1995. Acetylation phenotyping using isoniazid in Canadian HIV+ patients with advanced disease, abstr. A26, p. 6. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. Washington, D.C.
32. Torres, R. A., M. Barr, M. Thorn, G. Gregory, S. Kiely, E. Chanin, C. Carlo, M. Martin, and J. Thornton. 1993. Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. Am. J. Med. 95:573-583.
33. Zuidema, J., E. S. M. Hilbers-Modderman, and F. W. H. M. Merkus. 1986. Clinical pharmacokinetics of dapsone. Clin. Pharmacokinet. 11:299-315.